Some four years into Jemperli’s commercial lifespan, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. | Some four years into ...

GSK is sticking to its plan to gradually monetize its stake in Haleon, the consumer health business the British pharma giant spun off in 2022. GSK has collected about 978 million pounds ($1.24 billion ...

A major deal between the UK and the US to lower proposed tariffs on pharmaceuticals to zero is expected imminently.

UK invites pharma executives to help design a new drug-pricing system following a fresh US–UK agreement that raises NHS costs but protects medicine exports.

The FDA’s docket in December includes decisions for two big biologic franchises: BMS’s Breyanzi and Amgen’s Uplizna.

GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal ...

Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK ...

GSK has escalated a dispute over rights to its cancer immunotherapy Jemperli, after its subsidiary Tesaro filed a complaint ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other best ...

Saurabh Jain, head of equity research at SMC Global and Kunal Rambia, trading strategist at The Street, answered investor ...

GSK struck a deal worth up to $1.7 billion with China-based Hansoh Pharma to pick up the rights to an antibody-drug conjugate (ADC), HS-20093, which is being investigated in cancer. The exclusive ...